We are live on ! Find out more
Broadfin Capital

Broadfin Capital Portfolio holdings

AUM $747M Turnover 50%
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+43.75%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$747M
AUM Growth
+$206M
Cap. Flow
-$7.76M
Cap. Flow %
-1.04%
Top 10 Hldgs %
63.69%
Holding
56
New
12
Increased
11
Reduced
13
Closed
16
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
0.3 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
0.3 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$15.6M
2
STAA icon
STAAR Surgical
STAA
+$15.2M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$14.8M
4
LNTH icon
Lantheus
LNTH
+$12.5M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$11.4M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$16.2M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$13.6M
3
NVRO icon
NEVRO CORP.
NVRO
+$12.9M
4
WMGI
Wright Medical Group Inc
WMGI
+$12.8M
5
ABBV icon
AbbVie
ABBV
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 53.91%
2 Miscellaneous 46.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
$142M 18.96%
440,000
– –
2019 Q3
1 quarter
IWM icon
2
PUT
iShares Russell 2000 ETF
IWM
$77.8B
$133M 17.75%
+800,000
New +$126M
2019 Q4
0 quarters
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$33.3M 4.46%
350,000
-350,000
-50% -$30.3M
2019 Q3
1 quarter
BHVN icon
4
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$32.7M 4.37%
600,000
+100,000
+20% +$4.95M
2019 Q2
2 quarters
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$27.2M 3.64%
4,300,066
– –
2013 Q2
26 quarters
VRAY
6
DELISTED
ViewRay, Inc.
VRAY
$23.5M 3.15%
5,574,366
+2,573,005
+86% +$8.32M
2018 Q3
5 quarters
AMRN icon
7
Amarin Corp
AMRN
$244M
$22.5M 3.01%
52,462
-25,989
-33% -$9.9M
2019 Q2
2 quarters
BHVN icon
8
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$22.3M 2.98%
409,338
-123,253
-23% -$6.1M
2018 Q4
4 quarters
ALKS icon
9
Alkermes
ALKS
$7.24B
$21.1M 2.82%
1,033,500
+784,500
+315% +$15.6M
2019 Q3
1 quarter
QTNT
10
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19M 2.54%
49,855
+34,519
+225% +$11.4M
2018 Q2
6 quarters
EIGR
11
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$18.4M 2.47%
41,212
-4,367
-10% -$1.55M
2018 Q4
4 quarters
STAA icon
12
STAAR Surgical
STAA
$1.1B
$16.3M 2.18%
+462,118
New +$15.2M
2019 Q4
0 quarters
XENT
13
DELISTED
Intersect ENT, Inc
XENT
$15.7M 2.1%
631,023
-148,111
-19% -$3M
2019 Q3
1 quarter
PGNX
14
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$15.6M 2.09%
3,060,923
+1,476,998
+93% +$7.81M
2019 Q3
1 quarter
NSTG
15
DELISTED
NanoString Technologies, Inc.
NSTG
$15.5M 2.07%
555,600
+444,800
+401% +$10.8M
2018 Q3
5 quarters
IOVA icon
16
Iovance Biotherapeutics
IOVA
$6.39B
$14.8M 1.98%
533,301
-597,800
-53% -$13.6M
2015 Q1
19 quarters
DERM icon
17
DELISTED
Dermira, Inc.
DERM
$13.6M 1.82%
896,334
+316,734
+55% +$2.73M
2019 Q3
1 quarter
SCTL
18
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$13.2M 1.77%
721,073
-380,279
-35% -$5.46M
2014 Q1
23 quarters
LNTH icon
19
Lantheus
LNTH
$6.53B
$12.7M 1.7%
+617,953
New +$12.5M
2019 Q4
0 quarters
VAPO
20
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$12.2M 1.63%
+125,387
New +$10.6M
2019 Q4
0 quarters
SIEN
21
DELISTED
Sientra, Inc.
SIEN
$11.5M 1.54%
128,699
-71,491
-36% -$5.39M
2019 Q2
2 quarters
VCEL icon
22
Vericel Corp
VCEL
$2.07B
$10.8M 1.44%
620,199
+383,149
+162% +$6.52M
2018 Q3
5 quarters
LJPC
23
DELISTED
La Jolla Pharmaceutical Company
LJPC
$10.6M 1.41%
2,688,068
+2,506,224
+1,378% +$14.8M
2014 Q1
23 quarters
ALXN
24
DELISTED
Alexion Pharmaceuticals
ALXN
$8.99M 1.2%
+83,100
New +$8.89M
2019 Q4
0 quarters
SLGL icon
25
Sol-Gel Technologies
SLGL
$212M
$8.95M 1.2%
52,182
-4,148
-7% -$358K
2018 Q1
7 quarters
1
2 3

Similar funds

CIBC Bank USA
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
Capital One National Association
Capital One National Association New York $756M AUM
Manikay Partners
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Broadfin Capital held 56 positions worth $747M, up 38% from $541M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Broadfin Capital's Q4 2019 filing shows 12 new, 11 increased, 13 reduced and 16 closed positions. Its largest new stake was STAAR Surgical: 462,118 shares worth $16.3M. The largest sale was Allergan plc, an estimated $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 59% a quarter earlier, followed by Miscellaneous.

  • Broadfin Capital's largest Q4 2019 buy was STAAR Surgical: 462,118 shares worth $16.3M.
  • Broadfin Capital added most to Alkermes in Q4 2019, an estimated $15.6M increase.
  • Broadfin Capital's biggest Q4 2019 reduction was Iovance Biotherapeutics, cutting an estimated $13.6M.
  • Broadfin Capital fully exited Allergan plc in Q4 2019, selling an estimated $16.2M.
  • Broadfin Capital's ten largest holdings make up 64% of its $747M portfolio in Q4 2019.
  • Broadfin Capital opened 12 new positions and closed 16 in Q4 2019.
  • Broadfin Capital's portfolio value rose 38% quarter-over-quarter to $747M.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.